Regeneron Pharmaceuticals, Inc. (REGN) — Stock Score Summary

Regeneron Pharmaceuticals, Inc. (REGN) has a MoatMap StockRank of 86/100 based on Quality (72/100), Value (48/100), and Momentum (49/100) factor scores. The current signal is STRONG BUY. Regeneron is an exceptional biotech company with high ROIC and a strong pipeline. However, it does not fit our specific 18-month macro themes (such as the CDMO pricing power cycle, as it is a primary drug developer rather than a pure-play CDMO), and its valuation leaves a smaller margin of safety.

Regeneron Pharmaceuticals, Inc. is a leading biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines for serious diseases, with a strong presence in areas like eye diseases, allergic/inflammatory conditions, and oncology. The company's proprietary VelocImmune antibody discovery platform and robust R&D capabilities enable the creation of blockbuster biologic drugs, establishing a significant competitive moat through intellectual property and scientific leadership. Regeneron's integrated approach from research to commercialization underpins its success.

Key Financial Metrics

Price$628.73
Market Cap$65.2B
P/E (TTM)15.36
P/E (Forward)11.69
Price/Book2.04
Return on Equity14.5%
Return on Invested Capital14.6%
Debt/Equity8.61
Gross Margin43.9%
Operating Margin20.7%
Revenue Growth19.0%
Dividend Yield0.6%
Free Cash Flow$3.3B

Regeneron Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Regeneron Pharmaceuticals, Inc.’s (REGN) StockRank?
MoatMap’s StockRank for Regeneron Pharmaceuticals, Inc. (REGN) is 86/100, with a Strong Buy signal. It is a composite of Quality (72), Value (48), and Momentum (49) factor ranks across MoatMap’s 19,000+ stock universe.
Does Regeneron Pharmaceuticals, Inc. have an economic moat?
Regeneron Pharmaceuticals, Inc. (REGN) has a Quality factor score of 72/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Regeneron Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Regeneron Pharmaceuticals, Inc. (REGN) is Strong Buy, based on a StockRank of 86/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Regeneron Pharmaceuticals, Inc. in?
Regeneron Pharmaceuticals, Inc. (REGN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksREGN deep dive reportAI ChampionsHow we score stocksSense-check another stock